Stay updated on TAK-861 in Narcolepsy Type 1 Clinical Trial
Sign up to get notified when there's something new on the TAK-861 in Narcolepsy Type 1 Clinical Trial page.

Latest updates to the TAK-861 in Narcolepsy Type 1 Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check43 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check57 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check64 days agoChange DetectedThe latest updates include the posting of results for various dosages of TAK-861, including 0.5 mg, 2 mg, and 7 mg, along with detailed analyses of sleep latency, cataplexy rates, and treatment-emergent adverse events, while previous entries regarding specific dosing schedules and earlier result submissions have been removed.SummaryDifference22%
- Check86 days agoChange DetectedResults have been submitted, replacing the previous status of no results posted.SummaryDifference0.1%
Stay in the know with updates to TAK-861 in Narcolepsy Type 1 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TAK-861 in Narcolepsy Type 1 Clinical Trial page.